DE60213084D1 - 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA - Google Patents

3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA

Info

Publication number
DE60213084D1
DE60213084D1 DE60213084T DE60213084T DE60213084D1 DE 60213084 D1 DE60213084 D1 DE 60213084D1 DE 60213084 T DE60213084 T DE 60213084T DE 60213084 T DE60213084 T DE 60213084T DE 60213084 D1 DE60213084 D1 DE 60213084D1
Authority
DE
Germany
Prior art keywords
antiarrhythmika
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60213084T
Other languages
English (en)
Other versions
DE60213084T2 (de
Inventor
Christina Hovdal
Anna Lundgren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60213084D1 publication Critical patent/DE60213084D1/de
Publication of DE60213084T2 publication Critical patent/DE60213084T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
DE60213084T 2001-04-12 2002-04-12 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA Expired - Fee Related DE60213084T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101329 2001-04-12
SE0101329A SE0101329D0 (sv) 2001-04-12 2001-04-12 Pharmaceutical formulation
PCT/SE2002/000726 WO2002083689A1 (en) 2001-04-12 2002-04-12 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds

Publications (2)

Publication Number Publication Date
DE60213084D1 true DE60213084D1 (de) 2006-08-24
DE60213084T2 DE60213084T2 (de) 2007-01-11

Family

ID=20283785

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213084T Expired - Fee Related DE60213084T2 (de) 2001-04-12 2002-04-12 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA

Country Status (26)

Country Link
US (1) US20050037067A1 (de)
EP (1) EP1389212B1 (de)
JP (1) JP2005500262A (de)
KR (1) KR20030088498A (de)
CN (1) CN1514839A (de)
AR (1) AR035806A1 (de)
AT (1) ATE332902T1 (de)
BG (1) BG108234A (de)
BR (1) BR0208828A (de)
CA (1) CA2443473A1 (de)
CZ (1) CZ20032774A3 (de)
DE (1) DE60213084T2 (de)
EE (1) EE200300495A (de)
HU (1) HUP0303486A3 (de)
IL (1) IL158033A0 (de)
IS (1) IS6989A (de)
MX (1) MXPA03009209A (de)
NO (1) NO20034529L (de)
NZ (1) NZ528561A (de)
PL (1) PL366629A1 (de)
RU (1) RU2003129230A (de)
SE (1) SE0101329D0 (de)
SK (1) SK12562003A3 (de)
TW (1) TWI257391B (de)
WO (1) WO2002083689A1 (de)
ZA (1) ZA200307756B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
AU2006329006B2 (en) * 2005-12-20 2013-02-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
CA2644179C (en) * 2007-11-21 2018-09-25 Pharmascience Inc. Novel pharmaceutical composition comprising a disintegration matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2014157603A1 (ja) * 2013-03-29 2014-10-02 アステラス製薬株式会社 経口投与用医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3732094A1 (de) * 1987-09-24 1989-04-06 Basf Ag Bispidinderivate als klasse iii-antiarrhythmika
US5110933A (en) * 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
PL350907A1 (en) * 1999-04-09 2003-02-10 Astrazeneca Ab Adamantane derivatives
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Also Published As

Publication number Publication date
JP2005500262A (ja) 2005-01-06
RU2003129230A (ru) 2005-04-10
CZ20032774A3 (cs) 2004-01-14
SK12562003A3 (sk) 2004-03-02
NO20034529D0 (no) 2003-10-09
NZ528561A (en) 2005-03-24
AR035806A1 (es) 2004-07-14
CN1514839A (zh) 2004-07-21
EE200300495A (et) 2003-12-15
ATE332902T1 (de) 2006-08-15
BR0208828A (pt) 2004-03-09
IL158033A0 (en) 2004-03-28
MXPA03009209A (es) 2004-01-29
EP1389212A1 (de) 2004-02-18
TWI257391B (en) 2006-07-01
PL366629A1 (en) 2005-02-07
SE0101329D0 (sv) 2001-04-12
HUP0303486A3 (en) 2005-04-28
IS6989A (is) 2003-10-10
DE60213084T2 (de) 2007-01-11
HUP0303486A2 (hu) 2004-01-28
CA2443473A1 (en) 2002-10-24
KR20030088498A (ko) 2003-11-19
WO2002083689A1 (en) 2002-10-24
EP1389212B1 (de) 2006-07-12
NO20034529L (no) 2003-12-08
ZA200307756B (en) 2005-01-03
US20050037067A1 (en) 2005-02-17
BG108234A (bg) 2005-04-30

Similar Documents

Publication Publication Date Title
DE60131971D1 (de) 1,3,8-TRIAZA-SPIROi4,5 DECAN-4-ONDERIVATIVE ALS NEUROKININREZEPTORANTAGONISTEN
BR0216099B1 (pt) "conjunto de desgaste".
NO20040558L (no) Atineoplastiske kombinasjoner.
ITTO20000976A0 (it) Composizioni acaricide.
NO20040654L (no) Gassmikrosfaere-liposomkompositter.
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
BR0201919B1 (pt) colheitadeira.
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
NO20040387L (no) Nedihullsfrigjoringskopling.
ITTO20020744A1 (it) Composizione.
ITTO20020745A1 (it) Composizione.
ES1048400Y (es) Bota-patin mejorada.
DK1497256T3 (da) Substituerede 1,5-diaminopentan-3-ol-forbindelser
AR027974A1 (es) 1-aril-ciclopropilmetilamino-1,3,5-triazinas substituidas
BR0103827B1 (pt) cola - pds.
ES1050481Y (es) Pieza de construccion.
ITMI20022028A1 (it) Fenton i.s.
IT1317827B1 (it) Composizioni solventi.
ES1050491Y (es) Chupete infantil.
BR8101236Y1 (pt) desensiladeira.
ITTO20020746A1 (it) Composizione.
ES1057516Y (es) Pieza rodapie mejorada.
DE60017150D1 (de) 1,4,5,6 -tetrahydropyrimidine-derivative als vitronectin-hemmer
ES1050980Y (es) Portalamparas.
ES1053113Y (es) Tenedor-expulsor.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee